Cell Therapy

News

Galapagos drops plan to split after 'market developments'

Shortly after announcing a plan to separate its drug and cell therapy businesses into two separate companies, Galapagos has had a change of heart.

R&D

For cell therapies, raw material quality hinges on the human...

When it comes to cell-based therapy manufacturing, the concept of quality management carries important distinctions from more traditional therapeutics production.

News

Abeona prices rare cell disorder gene therapy at $3.1m

Abeona Therapeutics' Zevaskyn has been approved in the US as a treatment for the rare skin disorder recessive dystrophic epidermolysis bullosa (DEB).

News

Alcon claims control of cell therapy firm Aurion

Eyecare giant Alcon has bought a majority stake in cell therapy start-up Aurion Biotech, replacing the company's chief executive.

Oncology

Patient-focused manufacturing models for personalised therap...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jason Bock, co-founder and CEO of CTMC, a first-of-its-kind cell therapy engine.

R&D

Paul Hasting and Jonah Comstock interview at JP Morgan 2025

JP Morgan Week 2025 – Paul Hastings

At JP Morgan last month, pharmaphorum caught up with Paul Hastings, the CEO of Nkarta, to talk about NK cells and autoimmune diseases.

Galapagos drops plan to split after 'market developments'

For cell therapies, raw material quality hinges on the human...

Abeona prices rare cell disorder gene therapy at $3.1m

Alcon claims control of cell therapy firm Aurion

Patient-focused manufacturing models for personalised therap...

JP Morgan Week 2025 – Paul Hastings

FDA points to liver injury with Amgen's Tavneos

Using AI-driven synthetic personas to take your insights fur...

Cell Therapy

Editor's Picks